{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04903197",
            "orgStudyIdInfo": {
                "id": "CVAY736J12101"
            },
            "secondaryIdInfos": [
                {
                    "id": "2020-005881-32",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Novartis",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma",
            "officialTitle": "A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-as-single-agent-and-in-combination-with-select-antineoplastic-agents-in-patients-with-non-hodgkin-lymphoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-01-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-05-25",
            "studyFirstSubmitQcDate": "2021-05-25",
            "studyFirstPostDateStruct": {
                "date": "2021-05-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Novartis Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.",
            "detailedDescription": "The primary objective of the study is to evaluate the safety and tolerability in patients with NHL and identify a maximum tolerated dose (MTD) and/or recommended dose (RD) of VAY736 single agent and in combination with other anti-cancer therapies.\n\nThis is a phase I/Ib, multi-center, open-label study with multiple treatment arms in an adaptive study design. The study is comprised of a dose escalation part and dose expansion part.\n\nIn dose escalation, the investigational drug VAY736 will be explored alone or in combination with partner therapies. Increasing doses of VAY736 alone or in combination will be given to small groups of patients to identify the MTD/RD in patients with NHL. In dose expansion, some or all the treatments from dose escalation will be tested at the recommended doses in patients with NHL. Combination partners may be added in the future by protocol amendment. The study is expected to be approximately 4 years in duration (from enrollment of first patient to discontinuation of last patient)."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma"
            ],
            "keywords": [
                "VAY736",
                "ianalumab",
                "lenalidomide",
                "non-Hodgkin lymphoma",
                "NHL",
                "Diffuse large B cell lymphoma",
                "DLBCL",
                "Follicular lymphoma",
                "FL",
                "Mantle cell lymphoma",
                "MCL",
                "Marginal zone lymphoma",
                "MZL"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1A",
                    "type": "EXPERIMENTAL",
                    "description": "VAY736 single agent dose escalation in patients with NHL subtypes of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL)",
                    "interventionNames": [
                        "Drug: VAY736"
                    ]
                },
                {
                    "label": "Arm 1B",
                    "type": "EXPERIMENTAL",
                    "description": "VAY736 single agent dose expansion in patients with DLBCL",
                    "interventionNames": [
                        "Drug: VAY736"
                    ]
                },
                {
                    "label": "Arm 2A",
                    "type": "EXPERIMENTAL",
                    "description": "VAY736 + lenalidomide dose escalation in patients with DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). Enrollment has been halted in this arm.",
                    "interventionNames": [
                        "Drug: VAY736",
                        "Drug: lenalidomide"
                    ]
                },
                {
                    "label": "Arm 2B",
                    "type": "EXPERIMENTAL",
                    "description": "VAY736 + lenalidomide dose expansion in patients with DLBCL. This arm will not be conducted.",
                    "interventionNames": [
                        "Drug: VAY736",
                        "Drug: lenalidomide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "VAY736",
                    "description": "VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.",
                    "armGroupLabels": [
                        "Arm 1A",
                        "Arm 1B",
                        "Arm 2A",
                        "Arm 2B"
                    ],
                    "otherNames": [
                        "ianalumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "lenalidomide",
                    "description": "Immune-modulatory agent that enhances activation of NK cells.",
                    "armGroupLabels": [
                        "Arm 2A",
                        "Arm 2B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and nature of dose limiting toxicities (DLTs)",
                    "description": "Safety and tolerability",
                    "timeFrame": "28 days (first cycle of treatment)"
                },
                {
                    "measure": "Incidence of Adverse events (AEs) and serious adverse events (SAEs)",
                    "description": "Incidence of AEs and SAEs is defined as number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Number of patients with dose interruptions and dose reductions",
                    "description": "Safety and tolerability",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Dose intensity",
                    "description": "Safety and tolerability",
                    "timeFrame": "4 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans)",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Best overall response (BOR) rate",
                    "description": "Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans)",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Area under curve (AUC) for VAY736 and combination partners",
                    "description": "PK parameters will be derived from serum concentrations",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Maximum observed drug concentration after single dose administration (Cmax) for VAY736 and combination partners",
                    "description": "PK parameters will be derived from serum concentrations",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Change from baseline in anti-drug antibodies (ADA)",
                    "description": "Blood samples will be collected to detect change in levels of antibodies to VAY736",
                    "timeFrame": "Baseline, 4 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients with confirmed diagnosis of relapsed/refractory B-cell NHL with all subtypes of DLBCL, follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) per WHO 2016 criteria. Patients in subtype arm e.g. DLBCL must have confirmed diagnosis of relapsed/refractory DLBCL.\n* Received and failed or be intolerant to standard of care therapy (at least two prior lines, including an anti-CD20 therapy for NHL)\n* Must have measurable disease and ECOG of 0 to 2\n\nExclusion Criteria:\n\n* Baseline laboratory results outside of protocol defined ranges\n* Patients with primary CNS lymphoma\n* History of hypersensitivity to VAY736 or any drugs in similar chemical classes (e.g. monoclonal antibodies)\n* Impaired cardiac function or clinically significant cardiac disease\n* History of or current interstitial lung disease or pneumonitis grade 2 or higher\n* HIV infection\n* Active hepatitis C infection and/or hepatitis B infection\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential unless they are using highly effective methods of contraception\n\nOther Inclusion/Exclusion criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "1-888-669-6682",
                    "email": "novartis.email@novartis.com"
                },
                {
                    "name": "Novartis Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "+41613241111"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Novartis Institutes of Biomedical Research",
                    "affiliation": "Novartis Institutes of Biomedical Research",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City Of Hope National Med Ctr",
                    "status": "WITHDRAWN",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "The Ohio State University James Cancer Hospital &",
                    "status": "WITHDRAWN",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "WITHDRAWN",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3004",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Nanjing",
                    "state": "Jiangsu",
                    "zip": "210029",
                    "country": "China",
                    "geoPoint": {
                        "lat": 32.06167,
                        "lon": 118.77778
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Shanghai",
                    "zip": "200032",
                    "country": "China",
                    "geoPoint": {
                        "lat": 31.22222,
                        "lon": 121.45806
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Tianjin",
                    "zip": "300020",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.14222,
                        "lon": 117.17667
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Gottingen",
                    "zip": "37075",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.53443,
                        "lon": 9.93228
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Koeln",
                    "zip": "50937",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.93333,
                        "lon": 6.95
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Leipzig",
                    "zip": "04103",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.33962,
                        "lon": 12.37129
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Brescia",
                    "state": "BS",
                    "zip": "25123",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.53558,
                        "lon": 10.21472
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "WITHDRAWN",
                    "city": "Milano",
                    "state": "MI",
                    "zip": "20133",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Rozzano",
                    "state": "MI",
                    "zip": "20089",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.38193,
                        "lon": 9.1559
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Koto ku",
                    "state": "Tokyo",
                    "zip": "135 8550",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.66667,
                        "lon": 139.81718
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Yamagata",
                    "zip": "990 9585",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 38.23333,
                        "lon": 140.36667
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Singapore",
                    "zip": "119228",
                    "country": "Singapore",
                    "geoPoint": {
                        "lat": 1.28967,
                        "lon": 103.85007
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28034",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Novartis Investigative Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008224",
                    "term": "Lymphoma, Follicular"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                },
                {
                    "id": "D000020522",
                    "term": "Lymphoma, Mantle-Cell"
                },
                {
                    "id": "D000016403",
                    "term": "Lymphoma, Large B-Cell, Diffuse"
                },
                {
                    "id": "D000018442",
                    "term": "Lymphoma, B-Cell, Marginal Zone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18831",
                    "name": "Lymphoma, Large B-Cell, Diffuse",
                    "asFound": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11221",
                    "name": "Lymphoma, Follicular",
                    "asFound": "Lymphoma, Follicular",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22307",
                    "name": "Lymphoma, Mantle-Cell",
                    "asFound": "Lymphoma, Mantle-Cell",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20554",
                    "name": "Lymphoma, B-Cell, Marginal Zone",
                    "asFound": "Marginal zone lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1866",
                    "name": "Diffuse Large B-Cell Lymphoma",
                    "asFound": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2361",
                    "name": "Follicular Lymphoma",
                    "asFound": "Follicular lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3601",
                    "name": "Mantle Cell Lymphoma",
                    "asFound": "Mantle Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3612",
                    "name": "Marginal Zone Lymphoma",
                    "asFound": "Marginal zone lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077269",
                    "term": "Lenalidomide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M1725",
                    "name": "Lenalidomide",
                    "asFound": "Respiratory",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M18396",
                    "name": "Interleukin-4",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                }
            ]
        }
    },
    "hasResults": false
}